Analytical Data
-
Gene name
MYF5
- Application
-
Alternative Names
MYF5；BHLHC2；Myogenic factor 5
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P13349
-
Expression Region
1-255aa
-
AA Sequence
MDVMDGCQFS PSEYFYDGSC IPSPEGEFGD EFVPRVAAFG AHKAELQGSD EDEHVRAPTG HHQAGHCLMW ACKACKRKST TMDRRKAATM RERRRLKKVN QAFETLKRCT TTNPNQRLPK VEILRNAIRY IESLQELLRE QVENYYSLPG QSCSEPTSPT SNCSDGMPEC NSPVWSRKSS TFDSIYCPDV SNVYATDKNS LSSLDCLSNI VDRITSSEQP GLPLQDLASL SPVASTDSQP ATPGASSSRL IYHVL
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MYF5, a member of the myogenic regulatory factor (MRF) family, plays a crucial role in the regulation of skeletal muscle development and differentiation. It is one of the key genes involved in myogenesis, influencing the formation of muscle precursor cells and their subsequent maturation into muscle fibers. The study of MYF5 recombinant protein has gained significant attention due to its potential applications in regenerative medicine, muscle disease therapies, and the understanding of muscle development disorders. Research has shown that MYF5 interacts with other MRFs, such as MYOD and myogenin, to orchestrate the complex genetic program that leads to muscle tissue formation. Recombinant MYF5 can be produced through genetic engineering techniques, allowing for detailed functional analyses in various biological contexts. Exploring the properties of MYF5 recombinant protein not only enhances our understanding of muscle biology but also paves the way for innovative approaches to treat conditions such as muscular dystrophies and other related muscle-wasting diseases. The ability to manipulate MYF5 expression and activity could lead to advancements in therapeutic strategies aimed at promoting muscle regeneration and improving muscle health. As research continues to uncover the intricate mechanisms governed by MYF5, the development of recombinant protein technologies holds promise for unlocking novel insights into muscle development and potential interventions for muscle-related diseases.
